Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label multicenter study of BLZ945 alone or with PDR001 in advanced solid tumors
MOH_2017-11-12_001907Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotuletinib and spartalizumab in glioblastoma (GBM), pancreatic cancer (PC), triple-negative breast cancer (TNBC) and 1 more (2 arms), sponsored by Novartis. Primary endpoint: Antitumor activity of BLZ945 in combination with PDR001. Started Apr 2018; status: completed.
02
Drugs
sotuletinibspartalizumab
03
Conditions
glioblastoma (GBM)pancreatic cancer (PC)triple-negative breast cancer (TNBC)advanced nonhematological malignancy
Beyond the preview
Go deeper on MOH_2017-11-12_001907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-12_001907.